ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

PET Better At Evaluating Response In Sarcoma

February 29, 2008

HHS Names Crawford FDA Deputy Commissioner; Williams Appointed Deputy For Oncology Division.

March 1, 2002

November issue of Business & Regulatory Report, an additional 8 pages, included in this issue.

November 19, 2004

Otis Brawley To Succeed Harmon Eyre As American Cancer Society’s Chief Medical Officer.

August 3, 2007

FDA Forms Office of Combination Products;

January 10, 2003

NIH To Replace RAC With New Committee

July 19, 1996